These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: AZT studies reinforce benefits of combination.
    Journal: AIDS Alert; 1995 Jan; 10(1):11-2. PubMed ID: 11362167.
    Abstract:
    A new anti-HIV drug, 3TC, taken with AZT is yielding exciting results. An analysis of 6,000 subjects followed for 4 years indicated that patients taking AZT in combination with ddC or ddI survived longer than those who switched to ddC or ddI alone. Data also showed that CD4 counts were the most significant marker for predicting survival, favoring early treatment. Three studies of patients taking AZT and 3TC show that the two antiretrovirals may have a synergistic effect that may increase benefits even more than other drug combinations. The data on the AZT-3TC combination demonstrate increased maintenance of CD4 cell counts, reduced levels of HIV, and continued viral suppression.
    [Abstract] [Full Text] [Related] [New Search]